Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i3.10
pages 223-237

Development of Safe and Effcacious Viral Vaccines for Animals

Tilahun Yilma
International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, and Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California
Paulo Verardi
Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, Connecticut
Leslie Jones
International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, University of California, Davis, California

RESUMO

We have taken a number of approaches to improve the safety and efficacy of recombinant vaccines for use in humans and animals, including: choice of the strain of vaccinia virus (VACV) used as a vector, insertional inactivation of virulence and immunoregulatory genes of VACV, and expression of cytokine genes that attenuate the vector by more than a million-fold without reduction in immunogenicity. These strategies are illustrated by providing examples of recombinant VACV (rVACV) vaccines we have developed for rinderpest, vesicular stomatitis, simian immunodeficiency virus, and smallpox. We constructed rVACVs expressing interferon-gamma (IFN -γ) and lacking the immune-modulating genes B8R, B13R, and B22R. IFN-γ is a cytokine with potent immunoregulatory, antineoplastic, and antiviral properties. These rVACVs replicated to high titers in tissue culture, yet were avirulent in both immunocompromised and immunocompetent mice with no detectable viral replication in these animals. A single immunization elicited potent humoral, T-helper, and cytotoxic T-cell immune responses in mice despite the absence of any detectable virus replication in vivo. IFN-γ co-expression and the inactivation of one or more VACV immune-modulating genes provide an optimized method for increasing the safety while maintaining the efficacy of rVACV vaccines for use in humans and animals.


Articles with similar content:

Targeted Delivery of Drugs to the Gastrointestinal Tract
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.18, 2001, issue 4
E. C. Lavelle
Glycosylated Cationic Liposomes for Cell-Selective Gene Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 2
Junzo Nakamura, Mitsuru Hashida, Koyo Nishida, Fumiyoshi Yamashita
The Potential of CpG Oligodeoxynucleotides as Mucosal Adjuvants
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Heather L. Davis, Risini D. Weeratna, Paul J. Payette
Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
Zhengrong Cui, Russell J. Mumper
Acquisition and Presentation of Tumor Antigens by Dendritic Cells
Critical Reviews™ in Immunology, Vol.35, 2015, issue 5
Guido Ferlazzo, Stefania Campana, Irene Bonaccorsi, Barbara Morandi